Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial

BACKGROUND: Sulfamethoxazole-trimethoprim (SMX/TMP) is a standard drug for the prophylaxis of Pneumocystis pneumonia (PJP) in immunosuppressed patients with systemic rheumatic diseases, but is sometimes discontinued due to adverse events (AEs). The objective of this non-blinded, randomized, 52-week...

Descripción completa

Detalles Bibliográficos
Autores principales: Utsunomiya, Masako, Dobashi, Hiroaki, Odani, Toshio, Saito, Kazuyoshi, Yokogawa, Naoto, Nagasaka, Kenji, Takenaka, Kenchi, Soejima, Makoto, Sugihara, Takahiko, Hagiyama, Hiroyuki, Hirata, Shinya, Matsui, Kazuo, Nonomura, Yoshinori, Kondo, Masahiro, Suzuki, Fumihito, Tomita, Makoto, Kihara, Mari, Yokoyama, Waka, Hirano, Fumio, Yamazaki, Hayato, Sakai, Ryoko, Nanki, Toshihiro, Koike, Ryuji, Kohsaka, Hitoshi, Miyasaka, Nobuyuki, Harigai, Masayoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241919/
https://www.ncbi.nlm.nih.gov/pubmed/28100282
http://dx.doi.org/10.1186/s13075-016-1206-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241919/
https://www.ncbi.nlm.nih.gov/pubmed/28100282
http://dx.doi.org/10.1186/s13075-016-1206-8

Ejemplares similares